Cargando…

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study

AIMS: Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is), which impacts the relationship between a trial population and the general type 2 diabetes (T2D) population. The aim of this study was to evaluate the repr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birkeland, Kåre I., Bodegard, Johan, Norhammar, Anna, Kuiper, Josephina G., Georgiado, Elena, Beekman‐Hendriks, Wendy L., Thuresson, Marcus, Pignot, Marc, Herings, Ron M. C., Kooy, Adriaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590461/ https://www.ncbi.nlm.nih.gov/pubmed/30537226 http://dx.doi.org/10.1111/dom.13612

Ejemplares similares

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden
por: Kristófl, R., et al.
Publicado: (2023)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network
por: Kuiper, Josephina G, et al.
Publicado: (2020)

Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries
por: Oppelt, Katja A., et al.
Publicado: (2021)

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
por: Sundström, Johan, et al.
Publicado: (2022)

Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes
por: Overbeek, Jetty A., et al.
Publicado: (2018)

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
por: Nathanson, David, et al.
Publicado: (2017)

Risk of heart failure among colon and rectal cancer survivors: a population‐based case–control study
por: Kuiper, Josephina G., et al.
Publicado: (2022)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

A steep increase in healthcare seeking behaviour in the last months before colorectal cancer diagnosis
por: Kuiper, Josephina G., et al.
Publicado: (2021)

A population‐based linked cohort of cancer and primary care data: A new source to study the management of cancer in primary care
por: Kuiper, Josephina G., et al.
Publicado: (2021)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
por: Norhammar, Anna, et al.
Publicado: (2023)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
por: Young, Katherine G., et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics
por: Overbeek, Jetty A, et al.
Publicado: (2023)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dbrbd260seangbsils9argat40